Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F15%3A33157502" target="_blank" >RIV/61989592:15310/15:33157502 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61389030:_____/15:00448652

Výsledek na webu

<a href="http://www.tandfonline.com/doi/full/10.1517/13543776.2015.1045414" target="_blank" >http://www.tandfonline.com/doi/full/10.1517/13543776.2015.1045414</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1517/13543776.2015.1045414" target="_blank" >10.1517/13543776.2015.1045414</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014)

Popis výsledku v původním jazyce

Introduction: Cell cycle deregulation is a common characteristic of cancer cells. Progression through the cell cycle is controlled by enzymes known as cyclin-dependent kinases (CDKs), whose activity can be upregulated by a wide range of molecular mechanisms. Based on these observations, small molecule CDK inhibitors are being developed as potential cancer therapeutics. Some of these compounds have entered Phase Ill clinical trials and one of them, palbociclib, recently received accelerated approval from the FDA. However, the complexity of CDK biology and the undesired side effects of the existing inhibitors mean that the hunt for new CDK-targeting drug candidates continues. Areas covered: This article reviews patent applications related to small molecule CDK inhibitors published between 2009 and 2014. Expert opinion: Clinical trials with pan-specific inhibitors have generally yielded unambiguously positive outcomes. However, better results have been achieved with highly specific inhibitors of CDK4/CDK6. This may be due to several factors and has generated considerable interest in the discovery of new mono-specific CDK inhibitors. The development of such compounds is challenging because all CDKs have very similar active sites. Aside from this issue of selectivity, another key challenge is the identification of patients who will benefit from specific therapies.

Název v anglickém jazyce

Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014)

Popis výsledku anglicky

Introduction: Cell cycle deregulation is a common characteristic of cancer cells. Progression through the cell cycle is controlled by enzymes known as cyclin-dependent kinases (CDKs), whose activity can be upregulated by a wide range of molecular mechanisms. Based on these observations, small molecule CDK inhibitors are being developed as potential cancer therapeutics. Some of these compounds have entered Phase Ill clinical trials and one of them, palbociclib, recently received accelerated approval from the FDA. However, the complexity of CDK biology and the undesired side effects of the existing inhibitors mean that the hunt for new CDK-targeting drug candidates continues. Areas covered: This article reviews patent applications related to small molecule CDK inhibitors published between 2009 and 2014. Expert opinion: Clinical trials with pan-specific inhibitors have generally yielded unambiguously positive outcomes. However, better results have been achieved with highly specific inhibitors of CDK4/CDK6. This may be due to several factors and has generated considerable interest in the discovery of new mono-specific CDK inhibitors. The development of such compounds is challenging because all CDKs have very similar active sites. Aside from this issue of selectivity, another key challenge is the identification of patients who will benefit from specific therapies.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Opinion on Therapeutic Patents

ISSN

1354-3776

e-ISSN

—

Svazek periodika

25

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

18

Strana od-do

953-970

Kód UT WoS článku

000361269100002

EID výsledku v databázi Scopus

—